The purpose of the study is to evaluate how effective Milrinone, given through an intravenous infusion, is compared to a placebo in improving the neurological outcomes of patients three months after experiencing vasospasm following an aneurysmal subarachnoid hemorrhage. Participants in the study will receive either the Milrinone treatment or a placebo, and their progress will be monitored over a period of time to assess their recovery and overall health outcomes.

Throughout the study, various aspects of the participants’ health will be evaluated, including their recovery in terms of brain function and quality of life. The study will also look at the success of the treatment in terms of reducing the narrowing of blood vessels in the brain, as well as other health indicators such as the length of hospital stay and any changes in blood pressure or metabolism. The goal is to gather information that could help improve treatment strategies for patients with this serious condition.

The purpose of the study is to evaluate whether this treatment can improve the chances of patients achieving a good level of independence in their daily activities six months after the hemorrhage. Participants in the study will receive either the dornase alfa treatment or a placebo, and their progress will be monitored over time. The study aims to determine if the treatment can lead to better recovery outcomes compared to those who do not receive it.

Throughout the study, participants will undergo various assessments, including evaluations of their neurological function and brain imaging tests like MRI scans. These assessments will help researchers understand the impact of the treatment on the brain and overall recovery. The study will also track any side effects or complications that may arise during the treatment period. The ultimate goal is to see if dornase alfa can help improve recovery and quality of life for patients who have suffered a subarachnoid hemorrhage.